These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35857825)

  • 1. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity.
    Hartwell BL; Melo MB; Xiao P; Lemnios AA; Li N; Chang JYH; Yu J; Gebre MS; Chang A; Maiorino L; Carter C; Moyer TJ; Dalvie NC; Rodriguez-Aponte SA; Rodrigues KA; Silva M; Suh H; Adams J; Fontenot J; Love JC; Barouch DH; Villinger F; Ruprecht RM; Irvine DJ
    Sci Transl Med; 2022 Jul; 14(654):eabn1413. PubMed ID: 35857825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters.
    Agbayani G; Akache B; Renner TM; Tran A; Stuible M; Dudani R; Harrison BA; Duque D; Bavananthasivam J; Deschatelets L; Hemraz UD; Régnier S; Durocher Y; McCluskie MJ
    Eur J Immunol; 2024 Jun; 54(6):e2350620. PubMed ID: 38561974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
    Park SI; Park S; Lee K; Kwak HW; Kim YK; Park HJ; Bang YJ; Kim JY; Kim D; Seo KW; Lee SJ; Kim H; Kim Y; Kim DH; Park HJ; Jung SY; Ga E; Hwang J; Na W; Hong SH; Lee SM; Nam JH
    Vaccine; 2024 Jan; 42(2):69-74. PubMed ID: 38097457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
    Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models.
    Zhou R; Wang P; Wong YC; Xu H; Lau SY; Liu L; Mok BW; Peng Q; Liu N; Woo KF; Deng S; Tam RC; Huang H; Zhang AJ; Zhou D; Zhou B; Chan CY; Du Z; Yang D; Au KK; Yuen KY; Chen H; Chen Z
    EBioMedicine; 2022 Jan; 75():103762. PubMed ID: 34942445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters.
    Zhou P; Watt J; Mai J; Cao H; Li Z; Chen Z; Duan R; Quan Y; Gingras AC; Rini JM; Hu J; Liu J
    Front Immunol; 2024; 15():1430928. PubMed ID: 39281669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.
    Slamanig S; González-Domínguez I; Chang LA; Lemus N; Lai TY; Martínez JL; Singh G; Dolange V; Abdeljawad A; Kowdle S; Noureddine M; Warang P; Singh G; Lee B; García-Sastre A; Krammer F; Schotsaert M; Palese P; Sun W
    EBioMedicine; 2024 Jul; 105():105185. PubMed ID: 38848648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2.
    Li L; Wang M; Hao J; Han J; Fu T; Bai J; Tian M; Jin N; Zhu G; Li C
    Int J Biol Macromol; 2021 Nov; 190():409-416. PubMed ID: 34499954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques.
    McMahan K; Wegmann F; Aid M; Sciacca M; Liu J; Hachmann NP; Miller J; Jacob-Dolan C; Powers O; Hope D; Wu C; Pereira J; Murdza T; Mazurek CR; Hoyt A; Boon ACM; Davis-Gardner M; Suthar MS; Martinot AJ; Boursiquot M; Cook A; Pessaint L; Lewis MG; Andersen H; Tolboom J; Serroyen J; Solforosi L; Costes LMM; Zahn RC; Barouch DH
    Nature; 2024 Feb; 626(7998):385-391. PubMed ID: 38096903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination.
    Cokarić Brdovčak M; Materljan J; Šustić M; Ravlić S; Ružić T; Lisnić B; Miklić K; Brizić I; Pribanić Matešić M; Juranić Lisnić V; Halassy B; Rončević D; Knežević Z; Štefan L; Bertoglio F; Schubert M; Čičin-Šain L; Markotić A; Jonjić S; Krmpotić A
    Eur J Immunol; 2022 Jun; 52(6):936-945. PubMed ID: 35304741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission.
    Li W; Wang T; Rajendrakumar AM; Acharya G; Miao Z; Varghese BP; Yu H; Dhakal B; LeRoith T; Karunakaran A; Tuo W; Zhu X
    Nat Commun; 2023 Nov; 14(1):7114. PubMed ID: 37932271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Americo JL; Cotter CA; Earl PL; Liu R; Moss B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
    Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
    Front Immunol; 2021; 12():772240. PubMed ID: 34858430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response.
    Chen L; Zhang H; Li M; Wu B; Zhang Z; Gong R
    Front Immunol; 2022; 13():1005321. PubMed ID: 36466882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
    Hsieh HC; Chen CC; Chou PH; Liu WC; Wu SC
    Antiviral Res; 2023 Dec; 220():105752. PubMed ID: 37949318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
    Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.